Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.048 AUD | 0.00% | 0.00% | +118.18% |
May. 01 | Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6% | MT |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.22M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.32M | Net income 2023 | -2M -1.32M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 730K | Net cash position 2023 | 401K 265K | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 63.89% |
1 month | +41.18% | ||
3 months | +108.70% | ||
6 months | +71.43% | ||
Current year | +118.18% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 0.048 | 0.00% | 8,000 |
24-05-02 | 0.048 | -2.04% | 42,041 |
24-05-01 | 0.049 | +2.08% | 424,486 |
Delayed Quote Australian S.E., May 03, 2024 at 12:04 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+118.18% | 5.33M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- ANR Stock